

Regulatory fees for human medicinal products valid from 1st of January 2026

<i>Marketing authorisation application (national)</i>	<i>Human</i>
Complete dossier/well established use(WEU)/fixed combinations, Directive 2001/83/EF art. 8(3), 10a, 10b	512 044
Hybrid/Generic/Biosimilar/Informed consent, Directive 2001/83/EF art. 10(1), 10(3), 10(4), 10c	192 016
Additional formulations and strengths applied at the same time	19 202
Annex I: applications except new formulations/strengths	115 209
Annex I (Line extension): new formulations and strengths	128 012
Duplicate application (applied at the same time)	38 402
Application for registration of a traditional herbal medicinal product, with HMPC-monography	192 016
Application for registration of a traditional herbal medicinal product, without HMPC-monography (upon agreement)	256 023
Marketing authorisation application for natural remedies	256 023
Withdrawal of application before procedure start – administrative fee	25 602

<i>Variation applications and applications for renewal (national)</i>	<i>Human</i>
Type IB variation which leads to changes in the SmPC, PL and labeling ^{1 2}	10 881
Type II variation: change in therapeutic indication ^{1 2 3}	96 009
Type II variation: change in legal status ^{1 2}	96 009
Other type II variations ^{1 2 4}	16 002
Renewal ⁵	51 204
Traditional herbal medicinal products: type II variation – change in traditional use indication ^{1 2 3}	28 802
Traditional herbal medicinal products: type IB variation which leads to changes in the SmPC, PL and labeling ^{1 2}	10 881
Traditional herbal medicinal products; other type II variations ^{1 2}	16 002
Traditional herbal medicinal products; renewal ⁵	25 602

<i>Parallel import (national)</i>	<i>Human</i>
Application for marketing authorisation	20 481
Renewal ⁵	6 400

MRP where Norway is the RMS

<i>Marketing authorisation application (MRP-RMS)</i>	Human
Agreement on RMS-ship ⁶	64 005
Initiating MRP, regardless of legal basis ⁷	128 012
Repeat use, regardless of legal basis	128 012
Annex I: applications except new formulations and strengths	115 209
Annex I (line extension): new formulations and strengths	160 013

<i>Variation applications and applications for renewal (MRP-RMS)</i>	Human
Type IB variation which leads to changes in the SmPC, PL and labeling ¹²	14 079
Type II variation: change in therapeutic indication ¹²³	96 009
Other type II variations ¹²⁴	15 362
Worksharing: change in therapeutic indication ³⁸	96 009
Worksharing: type IB variation which leads to changes in the SmPC, PL and labeling ¹²⁸	12 802
Worksharing: harmonisation of SmPC	32 002
Worksharing: other type II variations ⁸	16 002
Renewal ⁵	51 204
Traditional herbal medicinal products: type IB variation which leads to changes in the SmPC, PL and labeling ¹²	10 241
Traditional herbal medicinal products: type II variations ¹²	15 362
Traditional herbal medicinal products: renewal ⁵	25 602

MRP where Norway is CMS

<i>Markering authorisation application (MRP-CMS)</i>	Human
Complete dossier/well established use(WEU)/fixed combinations, Directive 2001/83/EF art. 8(3), 10a, 10b.	128 012
Hybrid/Generic/Biosimilar/Informed consent, Directive 2001/83/EF art. 10(1), 10(3), 10(4), 10c.	96 009
Additional formulations and strengths applied at the same time	19 202
Annex I: applications except new formulations and strengths	64 005
Annex I (Line extension): New formulations and strengths	64 005
Application for registration of a traditional herbal medicinal products, with HMPC-monography	96 009
Application for registration of a traditional herbal medicinal products, without HMPC-monography (upon agreement)	128 012
Withdrawal of application before procedure start – administrative fee	25 602

<i>Variation applications and applications for renewal (MRP-CMS)</i>	Human
Type IB variation which leads to changes in the SmPC, PL and labeling ¹²	8 321
Type II variation: change in therapeutic indication ¹²³	44 804
Other type II variations ¹²⁴	12 802
Worksharing: change in therapeutic indication ³⁸	38 402
Worksharing: type IB variation which leads to changes in the SmPC, PL and labeling ¹²⁸	12 802
Worksharing: harmonisation of SmPC	25 602
Worksharing: other type II variations ⁸	12 802
Renewal ⁵	21 762
Traditional herbal medicinal products: type IB variation which leads to changes in the SmPC, PL and labeling ¹²	6 400
Traditional herbal medicinal products: type II variations ¹²	8 959
Traditional herbal medicinal products: renewal ⁵	6 400

DCP where Norway is the RMS

<i>Application for marketing authorisation (DCP-RMS)</i>	Human
Agreement on RMS-ship	64 005
Complete dossier/well established use(WEU)/fixed combinations, Directive 2001/83/EF art. 8(3), 10a, 10b.	448 040
Hybrid/Generic/Biosimilar/Informed consent, Directive 2001/83/EF art. 10(1), 10(3), 10(4), 10c.	192 016
Additional formulations and strengths applied at the same time	19 202
Annex I: applications except new formulations and strengths	140 811
Annex I (Line extension): new formulations and strengths	160 013
Application for registration of a traditional herbal medicinal products, with HMPC-monography	192 016
Application for registration of a traditional herbal medicinal products, without HMPC-monography (upon agreement)	320 028

DCP where Norway is CMS

<i>Application for marketing authorisation (DCP-CMS)</i>	Human
Complete dossier/well established use(WEU)/fixed combinations, Directive 2001/83/EF art. 8(3), 10a, 10b.	128 012
Hybrid/Generic/Biosimilar/Informed consent, Directive 2001/83/EF art. 10(1), 10(3), 10(4), 10c.	96 009
Additional formulations and strengths applied at the same time	19 202
Duplicate application (applied at the same time)	38 402
Annex I: applications except new formulations/strengths	64 005
Annex I (Line extension): new formulations/strengths	64 005
Application for registration of a traditional herbal medicinal products, with HMPC-monography	96 009
Application for registration of a traditional herbal medicinal products, without HMPC-monography (upon agreement)	128 012
Withdrawal of application before procedure start – administrative fee	25 602

<i>Homeopathic medicinal products</i>	<i>Human</i>
Application for registration. The fee covers all dilutions of one pharmaceutical form of a product	25 261
Type II variation	1 279
Renewal	1 279

<i>Clinical studies</i>	<i>Human</i>
New application – Norway as reference member state (Regulation nr. 536/2014)	78 588
New application – Norway as concerned member state (Regulation nr. 536/2014)	33 680
Variations (Directiv EC 2001/20 og Regulation nr. 536/2014)	6 736
Safety assessments – Norway as reference member state	4 491
Safety assessments – Norway as concerned member state	2 245

<i>Applications for WHO-certificates</i>	<i>Human</i>
WHO-certificate	6 250

Note

- 1 For variations including several formulations and strengths of the same product, one fee is invoiced
- 2 Variations leading to other consequential variations are invoiced as one.
- 3 Not applicable for linguistic changes, moving of text or information on limited documentation on the use in children etc. These are other type II variations
- 4 Applicable for posology changes
- 5 Applicable for each Marketing Authorisation
- 6 Applicable per procedure/agreement. Non refundable
- 7 Applicable independent of legal basis for the submission
- 8 Applicable independent of legal basis for the submission

Please note:

- For grouped variations, according to Variation Regulation EC 1234/2008, the fee will be equal to the sum of each variation applicable for a fee.
- Marketing Authorisations issued without national Product Information will also be applicable for a fee
- Type IA and Type IB variations without changes to the SmPC, Patient Information Leaflet and labeling will not be charged